Based on publicly available information. This is for informational exchange only and does not constitute any investment advice.

Innovative drug development is a business of trading time for probability, buying hope through financing in the early stage and buying freedom through sales in the later stage. The coming-of-age ceremony for a biotech company is never the applause when a new drug is approved, but the moment it no longer needs financing to stay alive. The former is an honor; the latter is true independence. The story of Ascentage Pharma is weighed repeatedly by countless investors between these two tenses.

In the summer of 2026, Ascentage Pharma submitted documents to the U.S. Securities and Exchange Commission to issue up to $200 million in American Depositary Receipts. This is not an accidental "blood transfusion" but a structural destiny of its balance sheet. It is like a dancer on a high wire, holding a long pole in hand, which is round after round of financing.

Financing Cycle

R&D is always the front line of cash burn. Ascentage Pharma is advancing nine global registrational Phase III clinical trials in parallel, most of them international multicenter studies with simultaneous enrollment in North America, Europe, and Asia-Pacific. A single trial can cost hundreds of millions of yuan, and running submissions simultaneously in the U.S., Europe, and China multiplies expenses further. R&D spending rose to 698 million yuan in the first half of 2026, up 32% year-over-year.

Sales and administrative expenses are also expanding. After the launch of Lisaftoclax, the commercialization team has been built out, and sales costs have risen accordingly. On the revenue side, sales of the two products are still ramping up, with product revenue of 282.4 million yuan in the first half of 2026, up 32.6% year-over-year. But sales expenses reached 226.4 million yuan over the same period, up 64.3% year-over-year, and total operating expenses were 1.0427 billion yuan, up 36.1% year-over-year, also outpacing product revenue growth. The growth is real, but compared with the scale of expenses, it remains a drop in the bucket. Operating cash flow widened from a net outflow of 432 million yuan a year earlier to 581 million yuan. As of June 30, 2026, the company had cash and bank balances of 1.896 billion yuan, while borrowings due within one year reached 1.475 billion yuan, leaving a current ratio of only 1.2 times.

Losses, financing, more losses, more financing — this has formed a cycle that Ascentage Pharma has not broken for more than a decade. Each financing round lifts the valuation to a new level, and each round also supports the next batch of clinical trials. The paradox is: where is the exit of this cycle?

The deeper dilemma is that Ascentage Pharma does not want to stop the bleeding, but the means of stopping the bleeding conflict with the goal of staying alive. Cutting clinical trials can immediately save expenses, but it is also equivalent to extinguishing the future of the products. Slowing commercialization would cause already approved products to lose the window to seize the market. In an industry where clinical data is the only passport, any cost-cutting may come at the price of growth. Thus, apart from continuing to raise funds, there is almost no other choice. This is both its predicament and the common fate of the entire innovative drug industry.

The Takeda Deal

The R&D spending of Ascentage Pharma is mainly focused on Olverembatinib and Lisaftoclax. In June 2024, Ascentage Pharma reached an overseas option agreement with Takeda Pharmaceutical for Olverembatinib, receiving $100 million in upfront payment plus $75 million in equity investment. The deal was once interpreted by public opinion as a milestone for "Chinese innovative drugs going overseas," as if Ascentage Pharma had finally found a big tree to entrust its overseas business to. But a closer reading of the terms reveals it is a double-edged sword.

The agreement is called an "option": before Takeda exercises the option, Ascentage Pharma still has to fund and lead all POLARIS global Phase III trials on its own. The huge expenses and all failure risks of these three trials are borne solely by Ascentage Pharma. The $100 million paid by Takeda buys only a ticket to "look at the data and then decide whether to buy." More importantly, even if all POLARIS trials succeed, Takeda still has the right to abandon the option due to changes in the market environment, adjustments in its own pipeline priorities, or even a shift in commercial judgment. By then, the $100 million already paid will not be refunded, and the overseas rights will return entirely to Ascentage Pharma — provided it still has enough cash to catch this lost-and-regained asset.

In other words, the Takeda deal did not truly share the heaviest burden for Ascentage Pharma. Instead, it stacked two layers of uncertainty — whether the clinical trials succeed and whether Takeda exercises the option — onto Ascentage Pharma itself. The honey is sweet at first taste, but beneath the sugar coating is bitterness that must still be swallowed alone. This is actually a common "call option" structure in pharmaceutical BD: the buyer pays a premium for the right to decide after seeing the data; the seller receives the premium but must bear the downside R&D risk alone. For Takeda, this is a low-cost and steady move. For Ascentage Pharma, it means trading future certainty for current cash flow, and this cash flow happens to support the Phase III trials it must complete alone. The mismatch of these two certainties is precisely the most delicate tension of this transaction.

The Great Bet on Lisaftoclax

If the Takeda deal for Olverembatinib still left a glimmer of hope for a "takeover," then the global development of Lisaftoclax (APG-2575) is an outright self-bet. As the world's second approved selective Bcl-2 inhibitor, Ascentage Pharma did not sell the overseas rights of Lisaftoclax to anyone, but chose to independently advance all four global registrational Phase III trials, the GLORA series. Management's logic is clear and confident: Lisaftoclax has the safety advantage of rapid dose escalation and shows potential activity in venetoclax-resistant populations. In particular, GLORA-4 is the world's only Bcl-2 registrational Phase III trial targeting high-risk myelodysplastic syndromes (HR-MDS). Once successful, it would be a First-in-Disease exclusive moat.

The imagination space for this differentiated value is simply too large. Licensing it out too early would be equivalent to giving away future excess returns. Beside it, BeiGene's Sonrotoclax has already received accelerated approval in the United States for mantle cell lymphoma, and Venetoclax has been the absolute ruler of the global market for years. For Lisaftoclax to squeeze onto this table, it relies on the safety of rapid escalation, potential activity in resistant populations, and GLORA-4, a piece of uncultivated land. This is both the confidence behind Ascentage Pharma's bold bet and the price it must accept for bearing the risk alone. The scarcer the differentiation and the fewer the competitors, the more cautious potential early buyers become.

Confidence has its reasons, but the cost is equally heavy: all risks of global Phase III head-to-head clinical trials will be swallowed alone by Ascentage Pharma. If successful, Lisaftoclax could rank among the world's top Bcl-2 players, with four indications advancing together and enormous future commercial value. If it fails, billions in prior global clinical investment could vanish overnight. This is a gamble with almost no middle ground: winner takes all, loser exits. And standing at the table is not a deep-pocketed multinational pharmaceutical company, but an innovative drug company with net assets of only a few hundred million yuan, surviving entirely on financing.

But the pharmaceutical industry never lacks stories of "thriving domestically and faltering overseas." Furmonertinib is a footnote close at hand. The lesson of Furmonertinib is precisely this: no matter how impressive domestic commercialization numbers look, they prove only one dimension. Global Phase III is a separate exam that must be answered anew with entirely new data. Ascentage Pharma's two products currently have only the Chinese market. The domestic sales growth of Olverembatinib and Lisaftoclax is encouraging, but before them stands the same wall that Furmonertinib already hit: overseas Phase III is never a natural extension of domestic success.

Conclusion: How to Dance Safely on the Wire

Returning to the original question: when can Ascentage Pharma break out of the financing cycle? The answer lies in a delicate balance point. On one hand, it must keep cash flow from drying up before obtaining positive global Phase III results, which means continued financing, restrained spending, and avoiding unnecessary clinical failures as much as possible. On the other hand, it needs a bit of luck for the key GLORA and POLARIS trials to eventually read out positive data, converting all prior investment and waiting into commercial returns. Neither can be missing, and they are mutually causal: without cash, it cannot wait for data; without data, no amount of cash can fill an endless pit.

For a dancer on a high wire, the greatest taboo is not moving slowly, but losing balance. The brilliance of Ascentage Pharma lies in maintaining the rhythm of walking through repeated financing. Its peril also lies in the fact that every step forward could be a high-risk leap. When Phase III data finally lands and cash flow reconciles with returns, this dance will truly be complete. Until then, all it can do is steady its breathing, move forward step by step, and hold the long pole in its hands even more firmly. Perhaps one day, when Ascentage Pharma's cash flow truly outruns its cash burn, people looking back on these years on the wire will understand: it was not struggling at the edge of a cliff, but learning little by little how to walk above the abyss. And what is truly worth remembering is not which patch of flat ground it finally stood on, but the determination with which it never let go while dancing in midair.